MS Speaks

Lancet article (March 22) on the Phase III siponimod study--"Siponimod vs. placebo in secondary progress multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study"


http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30475-6/fulltext


This is getting attention in the financial sector--from Endpoints News, March 23--"Poised for an FDA pitch, Novartis lays out all its Phase 3 cards on MS drug siponimod":


https://endpts.com/poised-for-an-fda-pitch-novartis-lays-out-all-its-phiii-cards-on-ms-drug-siponimod/